S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item

Nevro (NVRO) Stock Price, News & Analysis

$13.23
+0.11 (+0.84%)
(As of 04/12/2024 ET)
Today's Range
$12.80
$13.36
50-Day Range
$12.73
$17.61
52-Week Range
$12.34
$39.67
Volume
472,131 shs
Average Volume
374,702 shs
Market Capitalization
$481.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.54

Nevro MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
62.8% Upside
$21.54 Price Target
Short Interest
Bearish
12.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.12mentions of Nevro in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.54) to ($2.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

Medical Sector

650th out of 927 stocks

Surgical & Medical Instruments Industry

70th out of 98 stocks

NVRO stock logo

About Nevro Stock (NYSE:NVRO)

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

NVRO Stock Price History

NVRO Stock News Headlines

Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00
How to Get Rich From A Miracle Drug Touted by Elon Musk
When it comes to the $15.7 trillion build out of A.I., we haven't even gotten started, folks. And that spells opportunity in 2024. Last year, a group of stocks dubbed "The Magnificent Seven" soared as investors piled into these A.I. leaders, sending shares of the group an average of 111%. Compare that to the S&P 500's 24% gain... it's no contest.
Where Nevro Stands With Analysts
NVRO Mar 2024 20.000 put
How to Get Rich From A Miracle Drug Touted by Elon Musk
When it comes to the $15.7 trillion build out of A.I., we haven't even gotten started, folks. And that spells opportunity in 2024. Last year, a group of stocks dubbed "The Magnificent Seven" soared as investors piled into these A.I. leaders, sending shares of the group an average of 111%. Compare that to the S&P 500's 24% gain... it's no contest.
Nevro just downgraded at Oppenheimer, here's why
Why Nevro Stock Lagged the Market on Thursday
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
Analyst Scoreboard: 4 Ratings For Nevro
Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript
Nevro: Q4 Earnings Snapshot
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
NVRO Mar 2024 22.500 call
Nevro Corp
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/13/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Fax
N/A
Employees
1,215
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.54
High Stock Price Target
$40.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+62.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

Net Income
$-92,210,000.00
Pretax Margin
-23.02%

Debt

Sales & Book Value

Annual Sales
$425.17 million
Book Value
$8.10 per share

Miscellaneous

Free Float
35,306,000
Market Cap
$481.57 million
Optionable
Optionable
Beta
0.89
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Roderick H. MacLeod (Age 57)
    Senior VP & CFO
    Comp: $729.61k
  • Mr. Kashif  RashidMr. Kashif Rashid (Age 50)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $703.35k
  • Mr. Kevin R. Thornal (Age 50)
    President, CEO & Director
  • Mr. Richard B. Carter (Age 53)
    Chief Accounting Officer
  • Mr. Christofer Christoforou (Age 54)
    Senior Vice President of Technical Operations
    Comp: $367.4k
  • Geeta Kaveti
    VP and Chief Compliance & Privacy Officer
  • Mr. Jon R. Shear
    Senior Vice President of Corporate Development
  • Meredith Vornholt
    Vice President of Global Marketing
  • Ms. Shana D. Ross M.B.A.
    Senior VP & Chief of Human Resources Officer
  • Dr. David Caraway M.D. (Age 67)
    Ph.D., Senior VP & Chief Medical Officer

NVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price target for 2024?

13 Wall Street analysts have issued 12 month target prices for Nevro's stock. Their NVRO share price targets range from $14.00 to $40.00. On average, they predict the company's stock price to reach $21.54 in the next twelve months. This suggests a possible upside of 62.8% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2024?

Nevro's stock was trading at $21.52 at the beginning of 2024. Since then, NVRO shares have decreased by 38.5% and is now trading at $13.23.
View the best growth stocks for 2024 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its earnings results on Wednesday, February, 21st. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.35. The medical equipment provider earned $116.18 million during the quarter, compared to the consensus estimate of $115.93 million. Nevro had a negative trailing twelve-month return on equity of 30.22% and a negative net margin of 21.69%.

What ETFs hold Nevro's stock?
What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.0 million-$99.0 million, compared to the consensus revenue estimate of $98.7 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVRO) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners